 Hallucinogens
"Hallucinogens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise.
| Descriptor ID |
D006213
|
| MeSH Number(s) |
D27.505.696.388 D27.505.954.427.300 D27.505.954.427.700.372
|
| Concept/Terms |
Hallucinogens- Hallucinogens
- Psychotomimetic Agents
- Agents, Psychotomimetic
- Hallucinogenic Agents
- Agents, Hallucinogenic
- Hallucinogenic Substances
- Substances, Hallucinogenic
- Psychedelics
- Psychedelic Agents
- Agents, Psychedelic
- Hallucinogenic Drugs
- Drugs, Hallucinogenic
|
Below are MeSH descriptors whose meaning is more general than "Hallucinogens".
Below are MeSH descriptors whose meaning is more specific than "Hallucinogens".
This graph shows the total number of publications written about "Hallucinogens" by people in UAMS Profiles by year, and whether "Hallucinogens" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 6 | 0 | 6 | | 2021 | 1 | 1 | 2 | | 2020 | 0 | 1 | 1 | | 2018 | 1 | 1 | 2 | | 2014 | 2 | 0 | 2 | | 2013 | 1 | 1 | 2 | | 2012 | 0 | 2 | 2 | | 2010 | 3 | 1 | 4 | | 2009 | 1 | 1 | 2 | | 2007 | 4 | 0 | 4 | | 2006 | 3 | 1 | 4 | | 2005 | 3 | 0 | 3 | | 2003 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 1997 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hallucinogens" by people in Profiles over the past ten years.
-
Livne O, Budney A, Borodovsky J, Walsh C, Shmulewitz D, Fink DS, Struble CA, Habib M, Aharonovich E, Hasin DS. Delta-8 THC use in US adults: Sociodemographic characteristics and correlates. Addict Behav. 2022 Oct; 133:107374.
-
Forsyth AD, Kulik MC, Richmond McKnight T, Perkins AD, Balla A. University of California Cannabis Research Workshop, May 2021: Meeting Summary. Cannabis Cannabinoid Res. 2022 Apr; 7(2):152-155.
-
Lazris D, Gaur D, Curseen K, Kavalieratos D, Maxwell M, Quest T, Zarrabi AJ. Integrated Medical Cannabis Consultations in a Palliative Care Program: Policies, Procedures, and Progress after Six Years of Practice. J Palliat Med. 2022 05; 25(5):802-806.
-
al'Absi M, DeAngelis B, Fiecas M, Budney A, Allen S. Effects of regular cannabis and nicotine use on acute stress responses: chronic nicotine, but not cannabis use, is associated with blunted adrenocortical and cardiovascular responses to stress. Psychopharmacology (Berl). 2022 May; 239(5):1551-1561.
-
Kelleghan AR, Sofis MJ, Budney A, Ceasar R, Leventhal AM. Associations of cannabis product source and subsequent cannabis use among adolescents. Drug Alcohol Depend. 2022 04 01; 233:109374.
-
Connor JP, Stjepanovic D, Budney AJ, Le Foll B, Hall WD. Clinical management of cannabis withdrawal. Addiction. 2022 Jul; 117(7):2075-2095.
-
Hasin DS, Borodovsky J, Shmulewitz D, Walsh C, Livne O, Struble CA, Aharonovich E, Fink DS, Budney A. Use of highly-potent cannabis concentrate products: More common in U.S. states with recreational or medical cannabis laws. Drug Alcohol Depend. 2021 12 01; 229(Pt B):109159.
-
Berquist MD, Fantegrossi WE. Effects of 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine on alcohol consumption in Long-Evans rats. Behav Pharmacol. 2021 08 01; 32(5):382-391.
-
Borodovsky JT, Sofis MJ, Grucza RA, Budney AJ. The importance of psychology for shaping legal cannabis regulation. Exp Clin Psychopharmacol. 2021 Feb; 29(1):99-115.
-
Timko C, Cucciare MA. Commentary on Socias et al. (2018): Clinical research perspectives on cannabis use in opioid agonist treatment. Addiction. 2018 12; 113(12):2259-2260.
-
Timko C, Han X, Woodhead E, Shelley A, Cucciare MA. Polysubstance Use by Stimulant Users: Health Outcomes Over Three Years. J Stud Alcohol Drugs. 2018 09; 79(5):799-807.
-
Smith DA, Bailey JM, Williams D, Fantegrossi WE. Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice. J Pharmacol Exp Ther. 2014 Dec; 351(3):485-91.
-
Fantegrossi WE, Gray BW, Bailey JM, Smith DA, Hansen M, Kristensen JL. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice. Psychopharmacology (Berl). 2015 Mar; 232(6):1039-47.
-
Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013 Dec 10; 233(1-3):416-22.
-
Fantegrossi WE, McCain KR, Moran JH, Hoffman RS. Not simply synthetic tetrahydrocannabinol. J Pediatr. 2013 Dec; 163(6):1797-8.
-
Carter LP, Reissig CJ, Johnson MW, Klinedinst MA, Griffiths RR, Mintzer MZ. Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans. Drug Alcohol Depend. 2013 Mar 01; 128(3):206-13.
-
Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D'Souza DC. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the ? opioid agonist Salvinorin A in humans. Biol Psychiatry. 2012 Nov 15; 72(10):871-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|